Month: March 2021

– Matinas to internally focus on its Lipid Nanocrystal (LNC) platform to improve the intracellular delivery of critical therapeutics – – Enrollment continues in second patient cohort of EnACT study of MAT2203 in cryptococcal meningitis; Data and Safety Monitoring Board (DSMB) evaluation of safety and efficacy data of key second patient cohort anticipated Q3 2021 – – Collaboration with National Institute of Allergy and Infectious Disease (NIAID) to formulate Gilead’s antiviral COVID-19 medication remdesivir has progressed into in vitro studies – – Data from ENHANCE-IT study of LYPDISO™ against Vascepa®support continued development of LYPDISO as a potential best-in-class prescription-only omega-3 with robust EPA-levels; partnership process ongoing – – Management to host conference call today, Monday, March 29th, at 8:00 a.m. ET – BEDMINSTER,...

Paris, March 29, 2021, Disclosure of Transactions in Own Shares In accordance with the authorization given by the shareholders’ annual meetingon June 16, 2020 to trade on its shares and pursuant to applicable law on share repurchase,Kering (LEI: 549300VGEJKB7SVUZR78) declares the following purchases of its own shares (FR0000121485) from March 22 to 26, 2021 (French only):Issuer’s name Issuer’s identifying code Date of transaction Identifying code of financial instrument Aggregated daily volume (in number of shares) Daily weighted average price of the purchased shares Market(MIC code)KERING 549300VGEJKB7SVUZR78 23/03/2021 FR0000121485 7 000 576.3377 XPARKERING 549300VGEJKB7SVUZR78 24/03/2021 FR0000121485 7 000 570.5468 XPARKERING 549300VGEJKB7SVUZR78 25/03/2021 FR0000121485 7 000 563.7425 XPARKERING 549300VGEJKB7SVUZR78 26/03/2021 FR0000121485 10...

Paris, le 29 mars 2021 Déclaration des Transactions sur Actions Propres Dans le cadre de l’autorisation consentie par l’Assemblée générale du 16 juin 2020 pour opérer sur ses actions et conformément à la réglementation relative aux rachats d’actions,Kering (LEI : 549300VGEJKB7SVUZR78) déclare ci-après les achats d’actions propres(FR0000121485) réalisés du 22 au 26 mars 2021 :Nom de l’émetteur Code identifiant de l’émetteur (code LEI) Jour de la transaction Code identifiant de l’instrument financier Volume total journalier (en nombre de titres) Prix pondéré moyen journalier d’acquisition des actions Code identifiant marchéKERING 549300VGEJKB7SVUZR78 23/03/2021 FR0000121485 7 000 576,3377 XPARKERING 549300VGEJKB7SVUZR78 24/03/2021 FR0000121485 7 000 570,5468 XPARKERING 549300VGEJKB7SVUZR78 25/03/2021 FR0000121485 7...

INDIANAPOLIS, March 29, 2021 (GLOBE NEWSWIRE) — Duke Realty Corporation (NYSE: DRE, or the “Company”), the largest domestic-only logistics REIT, announced today that its operating partnership, Duke Realty Limited Partnership, amended and restated its $1.2 billion unsecured revolving credit facility. The amended and restated credit facility matures March 2025 and allows two six-month extensions and includes an uncommitted incremental facility, which allows the credit facility to be increased by up to $800,000,000. Borrowings under the amended and restated facility will bear interest at the annual rate of LIBOR plus 0.775 percent (subject to a pricing grid for changes in the company’s credit rating) compared to a rate of LIBOR plus 0.875 percent (subject to a pricing grid for changes in the company’s credit rating) under its previous...

CD12 trial results also indicated that five out of six patients on ECMO recovered VANCOUVER, Washington, March 29, 2021 (GLOBE NEWSWIRE) — CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing Vyrologix™ (leronlimab-PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today the publication in the Journal of Translational Autoimmunity “Case study of a critically ill person with COVID-19 on ECMO successfully treated with leronlimab” viewable at: https://doi.org/10.1016/j.jtauto.2021.100097. Nader Pourhassan, Ph.D., President and Chief Executive Officer of CytoDyn, noted, “We are very thankful to Sohier Elneil, M.D., University College London, for her strong contributions to this important study and to Jacob Lalezari,...

København Ø, March 29, 2021 (GLOBE NEWSWIRE) —   I henhold til vedtægterne indkalder Investeringsforeningen Stonehenge hermed til ordinær generalforsamling den 13. april 2021. Indkaldelsen med dagsorden fremgår af vedhæftede dokument, som også kan downloades fra foreningens hjemmeside www.stonehenge.dk. Bestyrelsen forInvesteringsforeningen Stonehenge Vedhæftede filerGF-indkaldelse Stonehenge 2021.04.13 Vedtægter Stonehenge 2021.04.13 mark-up

LONDON, March 29, 2021 – Stolt-Nielsen Limited (Oslo Børs: SNI) will host a video conference to present the Company’s unaudited results for the first quarter of 2021 on Thursday, April 8, 2021 at 15:00 CEST (09:00 EST, 14:00 BST). The presentation and video conference will be hosted by: –           Mr. Niels G. Stolt-Nielsen – Chief Executive Officer, Stolt-Nielsen Limited–           Mr. Jens F. Grüner-Hegge – Chief Financial Officer, Stolt-Nielsen Limited Those who wish to watch the live broadcast may access it here The presentation will be published on our website:https://www.stolt-nielsen.com/en/investors/reports-presentations/ For additional information please contact: Jens F. Grüner-HeggeChief Financial OfficerUK +44 (0) 20 7611 8985j.gruner-hegge@stolt.com Ellie DavisonHead of Corporate CommunicationsUK +44...

Mise à disposition des documents préparatoires à l’assemblée générale ordinaire annuelle et extraordinaire Paris, le 29 mars 2021, à 12h Compte tenu des décisions gouvernementales liées à la crise sanitaire COVID 19, GROUPE PARTOUCHE informe ses actionnaires que son Assemblée Générale mixte se tiendra à huis clos, hors la présence physique des actionnaires, le mercredi 14 avril 2021 à 10 heures au siège social de la société sis 141bis rue de Saussure 75017 PARIS L’avis de réunion comportant l’ordre du jour et les projets de résolutions a été publié le 10 mars 2021 au Bulletin des Annonces Légales Obligatoires (BALO). Les modalités de participation et de vote à cette Assemblée figurent également dans le même avis.Les documents et renseignements prévus aux articles R. 225-73, R. 225-81, et R. 225-83 du Code de commerce...

RANCHO CUCAMONGA, Calif., March 29, 2021 (GLOBE NEWSWIRE) — Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced that the U.S. Food and Drug Administration (“FDA”) approved the Company’s Abbreviated New Drug Application (“ANDA”) for Dextrose injection 50% in the 50 mL Luer-Jet® Prefilled Syringe System. For the past 40 years, the company has sold and marketed the product under the “grandfather” exception to the FDA’s “Prescription Drug Wrap-Up” program. Net revenues for the Company’s Dextrose injection for the year ended December 31, 2020, were $7.6 million. Amphastar’s CEO and President, Dr. Jack Zhang, commented: “The FDA’s approval of Dextrose, a product often on the Agency’s Drug Shortage list, offers an opportunity to ensure quality products are produced at the highest standard and highlights Amphastar’s manufacturing capabilities...

ISS Says the Dissident Plan Is “Light on Details,” that the Dissidents “Do Not Appear to Have an Executive Team in Place to Run the Company,” and that Shareholders Would be Best Served by “Preventing Them from Obtaining Control” Taronis Board Previously Engaged in Settlement Discussions Consistent with ISS Recommendations but the Activist Group Refuses to Negotiate any Settlement that Does Not Include Control of the Board Taronis Board Urges Shareholders to IGNORE any WHITE Consent Solicitation Card and Reject the Activist Group’s Attempts to Disrupt the Company’s Positive Momentum Peoria, AZ, March 29, 2021 (GLOBE NEWSWIRE) — Taronis Fuels, Inc. (“Taronis” or “the Company”) (OTCQB:TRNF), a global producer of renewable and socially responsible fuel products, responded to a report issued by Institutional Shareholder Services (“ISS”)...